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flavonoids from pine needles of Cedrus
deodara contribute to anti-tumor in vitro
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Abstract
Background: Cedrus deodara is one of the traditional Chinese medicinal herbs that exhibits a line of biological
activities. The current study extracted the total flavonoids from the pine needles of Cedrus deodara (TFPNCD), and
investigated its anti-cancer effects in tumor cell lines.
Methods: The total flavonoids was extracted from pine needles of Cedrus deodara by ethanol hot refluxing and
purified by HPD722 macroporous resin. The contents of total flavonoids and the active ingredients of TFPNCD were
analyzed through UV and HPLC. MTT assay was used to investigate its inhibitory effect on tumor cell lines. The flow
cytometry was employed to determine the apoptosis and cell cycle distribution after treated TFPNCD on HepG2 cells.
Results: The TFPNCD, in which the contents of total flavonoid reached up to 54.28 %, and the major ingredients of
myricetin, quercetin, kaempferol and isorhamnetin in TFPNCD were 1.89, 2.01, 2.94 and 1.22 mg/g, respectively. The
MTT assays demonstrated that TFPNCD inhibited the growth of HepG2 cells in a dose-dependent manner, with the
IC50 values of 114.12 μg/mL. By comparison, TFPNCD inhibited the proliferation to a less extent in human cervical
carcinoma HeLa, gastric cancer MKN28 cells, glioma SHG-44 cells and lung carcinoma A549 than HepG2 cells. We
found that even at the lower doses, the total flavonoids effectively inhibited the proliferation of HepG2 cells.
Comparison of IC50 values implicated that HepG2 cells might be more sensitive to the treatment with total flavonoids.
TFPNCD was able to increase the population of HepG2 cells in G0 /G1 phase. Meanwhile, TFPNCD treatment increased
the percentage of apoptotic HepG2 cells.
Conclusion: These data suggested that TFPNCD might have therapeutic potential in cancer through the regulation of
cell cycle and apoptosis.
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Background
Pinaceae has been shown to comprise eleven genera, of
which Cedrus (true cedar) was first described by Trew in
1757 [1]. Cedrus contains at least four species: Cedrus
deodara (Roxb.) G. Don, Cedrus libani A. Rich., Cedrus
brevifolia (Hook. f.) Henry and Cedrus atlantica (Endl.)
Manetti ex Carriére [2, 3]. As one of the widely-used
traditional medicine, Cedrus deodara displays multiple
biological acitivities [4]. In Indian, the wood of Cedrus
deodara has long been used to treat inflammation and
rheumatoid arthritis [5, 6]. In the Dictionary of Chinese
Crude Drugs, Cedrus deodara has been described to dis-
play therapeutic potentials in expelling wind, removing
dampness, destroying parasites and relieving itches. Clin-
ically, it is widely used to alleviate arthralgia, traumatic in-
jury, sleeplessness, edema, eczema and acariasis. Recently,
the beneficial effects of pine needles have also been re-
ported in patients with rheumatism, cardiovascular dis-
eases, diabetes, obesity, liver and stomach diseases,
gonorrhea, chronic bronchitis and cancer.
As an important step to reveal the pharmacological
mechanism of Cedrus deodara, the chemical studies
have successfully extracted three kinds of compounds:
terpenes, lignans and flavonoids. As is case for Cedrus
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deodara, these chemical compounds alone exhibit thera-
peutic activities against pain, spasm, inflammation and
cancer. Their antibacterial and antivirus effects have also
been reported to date [7]. Previously, our lab has taken
great efforts to investigate the chemical constituents of
pine needles of C. deodara, and has successfully isolated
from ethyl acetate extract of pine needles nineteen flavo-
noids, which include myricetin, quercetin, kaempferol,
isorhamnetin and their flavonoid glycosides (Fig. 1)
[8, 9]. These four major flavonoids in total flavonoids of
pine needles of C. deodara (TFPNCD) share similar mo-
lecular structures (Fig. 1). Myricetin has been shown to
inhibit the proliferation and induce the apoptosis of
HepG2 cells probably by means of reducing the phos-
phorylation levels of several proteins such as Akt, extracel-
lular signal-regulated kinase 1/2 and BAD [10, 11].
Quercetin is also effective in the inhibition of p21-RAS ex-
pression in human colon cancer cell lines and in primary
colorectal tumors [12].
The current study was designed to extract and purify
TFPNCD. We set up the methods to analyze the con-
tents of total flavonoids in TFPNCD as well as the con-
centrations of myricetin, quercetin, kaempferol and
isorhamnetin in TFPNCD. We systematically investi-
gated the effects of TFPNCD on the proliferation of
tumor cells in vitro and revealed a pronounced change
in the cell cycle and apoptosis that was possibly required




ide (MTT) was purchased from Solarbio Co., Ltd.,
(Beijin, China). The DEAE Sepharose Fast Flow were
obtained from Pharmacia Biotechnology. RPMI-1640
medium was purchased from GIBCO (USA). Fetal
bovine serum (FBS) was provided by Sijiqing Corpor-
ation (Hangzhou, China). Benzylpenicillin sodium was ob-
tained from Dongfeng Pharmaceutical Co., Ltd., (Jiangxi,
China). Streptomycin sulfate was produced by North
China Pharmaceutical Group Corporation. The HPLC-
grade Acetonitrile was from YuWang Chemical Industry
Company (Shan Dong, China). All other chemicals and re-
agents were of analytical grade. Deionized water was pro-
duced with Water Purification system (AFX2-0501-P, Ever
Young Enterprises Development Co.LTD, China).
Plant materials
The pine needles of Cedrus deodara (Roxb) G. Don were
collected in Lanzhou (Gansu, north of China) in June
2014. To avoid any destruction of chemical components,
the collected materials were dried in the shade. The
plant sample was identified by Prof. HE Fu-jiang in
Gansu Provincial Academy of Medical Science. A frac-
tion of sample was preserved in the plant herbarium of
Gansu Provincial Academy of Medical Sciences for fu-
ture reference.
Preparation of TFPNCD
The powder (40 mesh) of pine needles of Cedrus
deodara (30 g) was extracted two times (2 h and 1 h)
with 40 % ethanol (25 times volume) and then filtered.
The filtrate was evaporated under reduced pressure by
using a rotary evaporator (BUCHI, Switzerland) to ob-
tain the crude extract solution, with the concentration
of 2.85 mg/mL. The crude extract solution (15 mL;
adjusted to pH 4.0) was loaded in glass columns which
were wet-packed with HPD722 macroporous resin
(10 g). The feed rate was set at 2 bed volume (BV) · h−1.
The adsorbate-laden column was washed with 4 BVof de-
ionized water, and then eluted with 2 BV of aqueous solu-
tion (70 % ethanol) at 2 BV · h−1. The eluting solution was
concentrated in the rotary evaporation apparatus and
dried under vacuum before further analysis. All the dy-
namic experiments were performed at room temperature.
Measurement of the total flavonoids content in TFPNCD
The total flavonoids in TFPNCD were estimated as rutin
equivalent. To draw the calibration curve, a series of
rutin solutions (concentration range: 4.58–54.9 μg/mL)
were prepared as below: the appropriate volumes of
rutin stock solution were diluted with 0.3 mL of 5 %
(w/v) NaNO2, 0.3 mL of 10 % Al(NO3)3 and 4 mL of
4 % (w/v) NaOH. The mixtures were allowed to stand
for 6 min before diluted to final total 25 mL with dis-
tilled water. Fifteen min later, the absorbance was
measured with a spectrometer (Shimadzu Co., Ltd,
Japan). The TFPNCD sample was prepared and ana-
lyzed as above. The total flavonoids content of
Fig. 1 Structures of four major flavonoids in pine needles of
Cedrus deodara
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TFPNCD was calculated based on the established
calibration curve.
Measurement of four flavonoids contents in TFPNCD
TFPNCD was analyzed by Agilent 1100 HPLC TC-C18
column (150 mm× 4.6 mm; 5 μm, USA) equipped with
UV-detector system. The mobile phase was metha-
nol(A)-water(B) with the gradient elution (0–7 min,
55 % A; 7–20 min, 80 % A; 20–25 min, 55 % A) at the
flow rate of 1.0 mL/min at 30 °C and the detection was
performed at 360 nm wavelength. The sample pre-
treatment process involved the reflux extraction with
60 % methanol for 1 h and with the ratio of liquor to
material of 25 mL/g, extracting solution hydrolysis with
10 % hydrochloric acid for 1 h. All tested solutions were
of spectra analytical grade and were filtered through
0.45 μm filters before use. The standard of myricetin
was purchased from Ronghe medical technology Co. Ltd
(Shanghai, China), while those of quercetin, kaempferol
and isorhamnetin were purchased from Chinese food
and Drug Inspection Institute (Beijing, China).
Cell culture
The Human Cervical Carcinoma HeLa Cells, gastric
cancer MKN28 cells, human lung carcinoma A549 Cells,
human hepatocellular carcinoma HepG2 cells and hu-
man glioma SHG-44 cells were purchased from the Cell
Bank of Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China). These cells were
cultured in RPMI-1640 medium (HyClone, USA), except
for HepG2 in DMEM medium (HyClone, USA). Both
culture media was were supplemented with 10 % fetal
bovine serum (Gibco, Australia), 50 U/mL each of peni-
cillin and streptomycin and incubated at 37 °C in a hu-
midified incubator containing 5 % CO2 in air. The
medium was changed twice a week.
Cell growth inhibition
Cancer cells at logarithmic growth phase were digested
by 0.25 % trypsin, adjusted to the concentration of 2 ×
104 cells/mL, inoculated into 96-well cell culture plates
(200 μL per well) and then cultured at 37 °C for 24 h.
After treatment with various concentrations of TFPNCD
(5, 10, 20, 30, 40, 50, 60, 80, 100 μg /mL) for 44 h, the
cell proliferation was measured by MTT assay according
to the manufacturer’s instructions. Briefly, 20 μL of
MTT reagent (5 mg/mL) was added to each cluster well
and incubated at 37 °C for 4 h. The medium with MTT
was then removed and 150 μL of DMSO was added to
solubilize the formazan crystals. The plates were agitated
gently for 6 min at room temperature. The absorbance
value per well was determined at 570 nm using a xMark
microplate reader (BioRad Co., USA). All assays were re-
peated three times. The cell proliferation inhibition rate (%)
was calculated as follows: Cell proliferation inhibition rate
(%) = (1 - mean OD value / control mean OD value) × 100.
Cell cycle analysis
The human hepatoma HepG2 cells during logarithmic
growth phase were routinely cultured with DMEM.
After digestion with 0.25 % trypsin, 5 × 105/mL cells
were inoculated into 6-well cluster and cultured at 37 °C
overnight. The cells were treated with different concen-
trations of TFPNCD (10, 20, 40, 80, 160 μg/mL) for 48 h
before digestion with trypsin. The cell suspension was
centrifuged for 5 min at 1000 rpm/min. The cell pellet
was washed three times with cold phosphate-buffered
saline (PBS), fixed with 70 % cold ethanol at 4 °C for
24 h, and then supplemented with 100 μL of 100 μg/mL
RNaseA for 30 min at temperature room. After two
washes with PBS, the cells were stained with 400 μL of
100 μg/mL PI and incubated in the dark for more than
5 min. The samples were placed in 12 × 75 Falcon tubes
and evaluated by a FACS Calibur flow cytometry
(Becton-Dickinson, USA).
Apoptosis measurement
An Annexin V-FITC/PI double staining method was car-
ried out according to the manufacturer’s instruction. Hu-
man hepatoma HepG2 in logarithmic growth phase were
seeded in 6-well culture clusters. After 48 h treatment with
different doses of TFPNCD, the cells were digested with
trypsin and collected. The cells were washed two times with
cold PBS and centrifuged for 5 min at 1000 rpm/min. The
adherent and floating cells were suspended in 400 μL of
Binding Buffer with the concentration of 5 × 105/mL. The
cells were incubated with 5 μL annexin V-FITC and 5 μL
PI in the dark for 15 min at room temperature, and the
apoptotic cells were analyzed by a FACS Calibur flow
cytometry (Becton-Dickinson, USA).
Statistical analysis
Statistical analysis was conducted by using SPSS 16.0 soft-
ware. All data were presented as mean ± standard devi-
ation values. Statistical differences between groups were
analyzed by one-way analysis of variance (ANOVA) and
Student’s t-test with statistical significance set at
p < 0.05 or p < 0.01.
Table 1 Linear relations
Compound Regression equation r Linear range/μg · mL-1
myricetin Y = 47.087X -11.842 0.9993 1 ~ 10
quercetin Y = 46.326X -11.270 0.9993 1 ~ 10
kaempferol Y = 58.578X -51.830 0.9993 4 ~ 40
isorhamnetin Y = 41.387X -9.354 0.9992 1 ~ 10
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Results
The content of total flavonoids in TFPNCD
The concentration of flavonoids was calculated by using
rutin as the calibration standard. A good linear relation-
ship was obtained when flavonoid contents ranged from
4.58 μg/mL to 54.9 μg/mL. The resultant regression equa-
tion was as follows: y = 0.0012 x + 0.0048 (R = 0.9993),
where y, x and R represented the absorbance at 510 nm,
the concentration of flavonoids (mg/mL) and the regres-
sion coefficient, respectively. The average recovery was
Fig. 2 HPLC chromatograms of reference substances (a) and sample (b). 1. myricetin; 2. quercetin; 3. kaempferol; 4. isorhamnetin
Fig. 3 Anti-proliferative effects of TFPNCD on hepatocellular carcinoma HepG2 cells. Cells were treated with different doses of TFPNCD (5, 10, 20,
30, 40, 50, 60, 80, 100 μg /mL) for 48 h before the measure of cell proliferation by MTT assay. Data were expressed as mean ± SD deviation values
obtained from three independent determinations. **P < 0.01 versus controls
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Fig. 4 Effects of TFPNCD on the cycle distribution of HepG2 cells. The cells were treated with different doses of TFPNCD (10, 20, 40, 80, 160 μg/mL) for
48 h. Cells were washed, fixed and stained with propidium iodide (PI) before Becton-Dickinson FACS Calibur flow cytometry analysis
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97.64 % ± 1.31 % (n = 6). By using this method, we found
that the content of total flavonoid in TFPNCD was about
54.28 %.
The contents of four flavonoids in TFPNCD
Myricetin, quercetin, isorhamnetin and kaempferol have
been identified as the marker components in TFPNCD.
We therefore determined their contents through the
standard method as described above. The calibration
curves were linear when the concentrations of myricetin,
quercetin and isorhamnetin were adjusted to 1 ~ 10 μg/mL.
A good linear curve was also obtained with kaempferol at
the concentration of 4 ~ 40 μg/mL (r ≥ 0.9992). The regres-
sion equations for the four compounds were summarized
in Table 1. In addition to the satisfactory reproducibility,
the time course required to measure the contents of myri-
cetin, quercetin, kaempferol and isorhamnetin in
TFPNCD was as short as 14.6, 27.2, 38.3 and 39.6 min
(Fig. 2). Our data showed that the contents of myricetin,
quercetin, kaempferol and isorhamnetin in TFPNCD were
1.89, 2.01, 2.94 and 1.22 mg/g, while their average recover-
ies were 100.14, 97.63, 102.11 and 100.45 %, respectively
(n = 6).
Anti-proliferative effects of TFPNCD in HepG2 cells
To observe the possible influence of TFPNCD on cell
proliferation, we treated the human cervical carcinoma
HeLa Cells, gastric cancer MKN28 cells, lung carcinoma
A549 Cells, hepatocellular carcinoma HepG2 cells and
glioma SHG-44 cells with different doses of TFPNCD
for 48 h before MTT assays. Our data demonstrated that
TFPNCD (5–100 μg/mL) inhibited the growth of HepG2
cells in a dose-dependent manner (Fig. 3). The IC50
values were 114.12 μg/mL, suggesting that TFPNCD dis-
played a more potent inhibition of HepG2 cells. By com-
parison, TFPNCD inhibited the proliferation to a less
extent in human cervical carcinoma HeLa, gastric cancer
MKN28 cells, glioma SHG-44 cells and lung carcinoma
A549 than HepG2 cells.
Effects of TFPNCD on cell cycle
Next, we investigated the potential effects of TFPNCD
on cell cycle. To this end, the HepG2 cells were incu-
bated with different doses of TFPNCD for 48 h, followed
by flow cytometric analysis. Our data showed that, with
the increase of TFPNCD doses from 10 to 160 μg/mL,
the percentage of cells in G0 /G1 phase was also grad-
ually increased. At 160 μg/mL, TFPNCD enhanced the
cell population at G0 /G1 phase to 76.67 ± 2.87 % rela-
tive to 51.72 ± 1.26 % in mock-treated control cells
(Fig. 4). The percentages of cells at different cell cycle phases
after TFPNCD treatment were summarized in Table 2.
Apoptosis effect of TFPNCD on HepG2 cells
Our data showed that the HepG2 cells in the lower left
quadrant were viable and negative for both annexin V
and PI. The early apoptotic cells in the upper left
quadrant were positive for annexin V but negative for
PI. The late apoptotic cells in the upper right quad-
rant were positive for annexin V and PI. The necrotic
cell population in the lower right quadrant was posi-
tive for PI and negative for annexin V (Fig. 5). Quan-
titative analysis demonstrated that the amount of
apoptotic HepG-2 cells (both early and late apoptosis)
significantly increased after exposure to TFPNCD for
48 h. As shown in Table 3, TFPNCD at the doses of
20, 40, 80, 160 μg/mL increased the apoptotic ratea
from 6.44 ± 0.97 % of control to 12.71 ± 1.29 % (n = 3,
p < 0.05), 20.53 ± 2.07 % (n = 3, p < 0.01), 33.86 ± 1.17 %
(n = 3, p < 0.01) and 64.56 ± 2.05 % (n = 3, p < 0.01),
respectively.
Discussion
Great efforts have to date been made to develop the
anti-cancer drugs. The natural products are attracting
increasing attention due to their many advantages
over chemical drugs, such as the low toxicity, safety
and cheapness [13]. In 1963, a crude extract from the
bark of the Pacific yew Taxus brevifolia, a kind of
scarce evergreen that grows slowly in the old-growth
forest of Pacific Northwest, was found in preclinical
studies to have cytotoxic activity against many tumors
[14]. Since then, a diterpenoid compound, paclitaxel,
was successfully isolated from the bark of the Taxus
brevifolia. Now paclitaxel has been substantiated to
be the major component that exerts anti-cancer ef-
fect. In 1992, paclitaxel was approved by the Food
and Drug Administration as one of the most import-
ant chemotherapeutic agents against a wide range of
tumors [15]. Currently, a series of paclitaxel analogues
have been discovered and synthesized to treat the pa-
tients with advanced cancer of the ovaries, breast,
lung, and kaposi sarcoma.
Table 2 Percentages of HepG2 cells in G0/G1-, S-, and G2/M-
phase (±s,n = 3)
Group Percentages (%)
G0/G1 S G2/M
0 (control) 51.72 ± 1.26 39.03 ± 1.14 9.25 ± 0.87
10 μg/mL 53.96 ± 1.34 37.86 ± 1.89 8.18 ± 2.05
20 μg/mL 55.84 ± 0.98 29.99 ± 2.01* 14.17 ± 0.83*
40 μg/mL 63.55 ± 1.65* 29.13 ± 1.02* 7.32 ± 1.64
80 μg/mL 64.61 ± 1.32* 29.81 ± 0.78* 5.58 ± 0.12*
160 μg/mL 76.67 ± 2.87** 13.38 ± 1.26** 9.95 ± 0.67
*P < 0.05,**P < 0.01 versus controls
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Fig. 5 Apoptotic effect of TFPNCD treatment in HepG2 cells. The cells were treated with different doses of TFPNCD (10, 20, 40, 80, 160 μg/mL) for
48 h and then stained with annexin V-FITC and propidium iodide (PI) as described in Materials and Methods. The stained cells were analyzed for
apoptosis by using a Becton-Dickinson FACS Calibur flow cytometry
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Cedrus deodara has been shown to contain the non-
volatile and volatile constituents. Most of non-volatile
constituents include terpenes, lignans, flavonoids and
fatty acids [16]. By using spectroscopic methods such as
1H NMR, 13C NMR, IR, and LC-MS, previous studies
have isolated from the dried heartwood powder of
Cedrus deodara three compounds: (−)-matairesinol,
(−)-nortrachelogenin, and a dibenzylbutyrolactollignan
(4, 4’, 9-trihydroxy-3, 3’-dimethoxy-9, 9’-epoxylignan).
Three compounds have been revealed to display po-
tent antioxidant activities. Thereafter, two lignans
were discovered in lead acetate-purified butanol sol-
uble fraction of wood of Cedrus deodara [17]. The
phytochemical screening of its leaf part further shows
the presence o flavanoids, alkaloids, tannins and sapo-
nins [18]. Recently, an isolated “CD lignan mixture”
from stem wood of the plant has been shown to contain
high concentrations of (−)-wikstromal (75–79 %),
(−)-matairesinol (9–13 %) and benzylbutyrolactol (7–
11 %). The in vitro assays demonstrate that this mixture
exhibits the pronounced anticancer activities. More im-
portantly, the pharmacological studies in animal models
of Ehrlich ascites carcinoma and colon carcinoma (CA-
51) have also consolidated its dose-dependent action
against several cancer cell lines such as cervix, colon, liver,
prostate and neuroblastoma in vivo [19–21]. The lignan
mixture might exert anti-cancer effects by regulating
annexin V binding, intracellular caspases activities and
DNA fragmentation [22–24].
Flavonoids are ubiquitously distributed in nature. As
the food-derived cancer preventive compounds, they
display potential therapeutic benefit in cancer and
may be considered as the candidates for chemothera-
peutic agents [25]. Investigation of the clinical use of
polyphenolic compounds, such as quercetin, kaemp-
ferol, apigenin, myricetin, baicalein, luteolin, isorham-
netin, chrysin, nobiletin, and tangeretin, might be
valuable strategies in the development of novel anti-
cancer drugs [26–29]. To improve their biological ac-
tivities and enhance their anticancer effects, it is also
important to chemically modify the structures of
natural flavonoids by introducing structural variations
into their backbone. The current study purified and
extracted the total flavonoids from pine needles of
Cedrus deodara. After successful measurement of the
content of total flavonoids in TFPNCD through
HPLC techniques, we systematically evaluated the
biological activity of total flavonoids against tumor
cells. Our data showed that even at the lower doses,
the total flavonoids effectively inhibited the proliferation
of HepG2 cells. Comparison of IC50 values implicated that
HepG2 cells might be more sensitive to the treatment
with total flavonoids.
Dysregulation of apoptosis is one of the key mecha-
nisms underlying cancer [30]. Activation of apoptotic
pathways in cancer cells is thus critical for cancer
therapy. The means by which an herbal product in-
duces apoptosis has become the subject of great
interest. In this study, we revealed that total flavo-
noids exhibited potent cytotoxicity against HepG2
cells. To gain insight into the mechanisms underlying
the anti-cancer effects of total flavonoids, we investi-
gated the possible changes in the cell cycle and apop-
tosis. We found that the total Flavonoids was able to
retard the HepG2 cells at G0 /G1 phase. Consistent
with these results, the apoptotic rate of HepG2 cells
was also increased by the total flavonoids in a dose-
dependent way. These data broadened our framework
for the understanding of the medicinal function of
Cedrus deodara, and provided evidence for the first
time that the total flavonoids exerted a potent inhibi-
tory effect on the tumor growth. Especially, the
TFPNCD might have therapeutic potential in cancer
by regulating cell cycle and apoptosis. The anti-cancer
action of the total flavonoids in vivo, however, re-
quires further studies in the future.
Conclusions
In summary, the present study demonstrates that the
total flavonoids of Cedrus deodara were able to to in-
hibit the tumor proliferation. The anticancer action of
TFPNCD might involve the regulation of cell cycle and
Table 3 The influence of flavonoids of Cedrus deodara (Roxb.) Loud. pine needle on HepG2 tumor cell apoptosis x  s; n ¼ 3ð Þ
Group Cell apoptosis distribution percentage and apoptosis rate
UL (%) UR (%) LL (%) LR (%) Apoptosis (%)
0 (control) 2.16 ± 0.13 1.78 ± 0.34 91.40 ± 1.83 4.66 ± 0.57 6.44 ± 0.97
10 μg/mL 1.57 ± 0.08 2.10 ± 0.23 91.25 ± 2.27 5.08 ± 0.61 7.18 ± 0.83
20 μg/mL 2.04 ± 0.12 8.05 ± 1.96* 85.25 ± 2.79* 4.66 ± 0.41 12.71 ± 1.29*
40 μg/mL 9.28 ± 1.76* 16.98 ± 0.72** 70.18 ± 1.24** 3.55 ± 0.56 20.53 ± 2.07**
80 μg/mL 14.62 ± 1.02** 31.68 ± 1.45** 51.51 ± 1.38** 2.18 ± 0.17 33.86 ± 1.17**
160 μg/mL 6.16 ± 0.66** 52.66 ± 2.82** 29.28 ± 1.65** 11.90 ± 1.17** 64.56 ± 2.05**
*P < 0.05,**P < 0.01 versus control
Shi et al. BMC Complementary and Alternative Medicine  (2016) 16:245 Page 8 of 9
apoptosis. An important step toward a better evaluation
of TFPNCD is to extensively study how this flavonoids
act in vivo in the future.
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